

SWIM

ACROSS AMERICA

★ MAKING WAVES TO DEFEAT CANCER ★

NASSAU-SUFFOLK Long Island



SWIM TO FIGHT CANCER ON LONG ISLAND



REGISTER TO SWIM:

[SWIMACROSSAMERICA.ORG/NS](https://swimacrossamerica.org/ns)

SATURDAY, AUGUST 3, 2024

THE SAA MISSION

We unite the swimming community by hosting benefit swims that raise money to fund life saving cancer research and clinical trials.

THE NEED

Doctors with ideas to fight cancer can't get the funding for clinical trials and research.

OUR SOLUTION

Host Charity Swims to raise money that funds clinical trials and cancer research.

YOUR IMPACT

Over \$90 million in SAA grants to our beneficiaries has turned into an estimated \$200 million in new funding that they might otherwise not have received.

SOUND TO COVE OPEN WATER SWIM SAA - NASSAU/SUFFOLK, LONG ISLAND

SATURDAY, AUGUST 3, 2024
PRYIBIL BEACH, GLEN COVE, NY

1/2-MILE, 1-MILE, 5K AND 10K SWIM OPTIONS

ALL PROCEEDS BENEFIT



Memorial Sloan Kettering
Cancer Center



24

COMMUNITIES
MAKING WAVES



100,000+

SWIMMERS

300

OPEN WATER
SWIMS

150+

OLYMPIANS
PARTICIPATED

4 FDA

- APPROVED TREATMENTS

Yervoy, Opdivo,
Tecentriq & Keytruda all
received initial grant
funding from SAA

DID YOU
KNOW?
FACTS
ABOUT
SWIM
ACROSS
AMERICA



THREE

TIMES OUR
SWIMMERS HAVE
CIRCUMNAVIGATED
THE EARTH



11

DEDICATED
SWIM ACROSS
AMERICA LABS



60+

GRANTS FUNDED BY
SWIM ACROSS AMERICA
ANNUALLY



5 TO 92

AGES OF
PARTICIPANTS

SAA Nassau-Suffolk Metrics

Over \$12 MILLION raised since 2001
500+ Swimmers & Volunteers annually
81% of Donations go directly to Beneficiaries

SAA Nassau-Suffolk 2024 Goals

\$900,000 in Total fundraising
\$250,000 corporate sponsorships

SAA Nassau-Suffolk Swims

Stay Tuned for 2024 Pool Swim Dates!

ANYONE CAN JOIN WITH THE SAA MY WAY VIRTUAL OPTION

SAA My WAY program enables our participants and teams to Make Waves in the Fight Against Cancer if you don't want to swim. You can Walk, Run, Bike, Hike, Climb... get CREATIVE !

WHEN: You decide - done on your timeline as an individual or as a team. Perfect for corporate teams to include everyone!

WHAT: All participants receive a SAA swag kit in the mail after registering! Learn more at swimacrossamerica.org/saamyway



NASSAU-SUFFOLK Long Island

MAKING WAVES SINCE 2001

BENEFITING



WITH GRATITUDE TO OUR SPONSORS



SAA NASSAU-SUFFOLK Teams



SWIM ACROSS AMERICA ★
NASSAU-SUFFOLK
IS PROUD TO HOST THE TOP TWO
FUNDRAISING TEAMS NATIONWIDE!

2023 TOP FUNDRAISING TEAMS	2023 TOP FUNDRAISING TEAMS
#1 - TEAM STACEY SWIM ACROSS AMERICA - NASSAU/SUFFOLK	#2 - TEAM CAROLYN SWIM ACROSS AMERICA - NASSAU/SUFFOLK
	



SAA-Nassau-Suffolk (Long Island) World Class Beneficiary Partners



Memorial Sloan Kettering
Cancer Center.

The goal of the Swim Across America laboratory at Memorial Sloan Kettering Cancer Center is to develop new approaches to cancer treatment through stimulating the immune system to attack cancer cells. Results from our laboratory are the basis of ongoing clinical trials at MSKCC in patients with melanoma, breast cancer, prostate cancer, kidney cancer and lymphoma. The lab has been one of the most successful in the world at moving lab discoveries into the clinic. The SAA lab was instrumental in the development of the first Melanoma US FDA-approved drug in 13 years.



The Swim Across Research Laboratory at Weill Cornell Cancer Center, led by Dr. Taha Merghoub, conducts immunotherapy research and clinical trials.



Cold
Spring
Harbor
Laboratory

We have been funding the important non small cell lung cancer research of Rafaella Sordella, PhD since 2008 at Cold Spring Harbor Laboratory. Her lab has been able to identify a subpopulation of cells that are intrinsically resistant to both conventional and targeted therapies and are more metastatic. At the molecular level they have determined that increased activation of the TGF-beta-IL-6 axis is driving all these phenotypes. Important drugs targeting the IL-6 signaling pathway are currently available. They are now focused on seeking to understand the efficacy of these drugs in a pre-clinical model, that will hopefully lead to the development of new lung cancer clinical trials.

SAA-Nassau-Suffolk (Long Island) World Class Beneficiary Partners



In 2011 we began assisting in the funding of a pediatric brain cancer project directed by Marc Symons, PhD at The Feinstein Institute for Medical Research of North Shore. Current therapies for the most common malignant childhood brain tumor, medulloblastoma in particular radiation therapy have long term side effects, including marked neurocognitive difficulties. Marc's lab has initiated a program to identify medulloblastoma radio-resistance genes and characterize their functions. Hopefully the identified radio-resistance genes will provide us with new drug targets for the development of more effective therapies for medulloblastoma.



Swim Across America has been funding the 'Stacey Leondis Fellowship' - research into the development of a targeted therapy for osteosarcoma, an adolescent bone cancer supervised by Dr. Richard Gorlick at Children's Hospital at Montefiore, since 2006. SAA-Nassau-Suffolk will continue funding Dr. Gorlick's research now that he is the division head and department chair of Pediatrics at The University of Texas MD Anderson Children's Cancer Hospital.



Dedicated, experienced support for women facing breast, ovarian, uterine, cervical or metastatic breast cancer.

MAKING CANCER HISTORY

“Swim Across America funding has played a major role in clinically developing the four FDA approved immunotherapy medicines ipilimumab, nivolumab, pembrolizumab and atezolizumab.”

Dr. Jedd Wolchok

Sandra and Edward Meyer
Cancer Center Director
Weill Cornell Medicine



MAKING CANCER HISTORY



Division of Pediatrics
T 713-834-6754 F 713-794-5042
1515 Holcombe Blvd., Unit 0087
Houston, Texas 77030-4009

July 30, 2022

Dear Swim Across America Friends:

This year has been a good one in our fight against osteosarcoma. Our Swim Across America Stacey Leondis Fellow, Yifei Wang, MD continues in our laboratory with your generous support. This year his work describing the comprehensive surface protein profiling of osteosarcoma was published but more importantly this work has launched intensive efforts to develop new more effective treatments.

Yifei's work has identified drugs that exist that may be effective in osteosarcoma as well as proteins that may be targeted that do not have drugs yet developed. While at one time we would have never envisioned developing drugs specifically for osteosarcoma, new approaches such as creating antibody-drug conjugates allows this to be feasible mixing and matching existing components, reducing both the cost and complexity of their development. Indeed, for rare diseases such as osteosarcoma this is paradigm shifting allowing an optimization never before possible. For one of the identified targets, the first critical step is in process which is creating a monoclonal antibody targeting that protein. For a second identified target, we are excited to reveal that the monoclonal antibody has been created and the production of a first batch of drug for validation that it is effective is underway.


In prior letters and conversations, we have mentioned we are very excited about one protein target which already has drugs and cell therapy approaches made to target it – B7H3 also known as CD276. Indeed, work on that target continues to move forward and activity of multiple antibody-drug conjugates targeting this protein have been validated as having activity in osteosarcoma. Laboratory studies are now investigating how to combine these drugs with both the existing treatments for osteosarcoma as well as together with other novel agents. Finally, and most importantly these drugs are moving rapidly to clinical trials in patients with osteosarcoma.

We are immensely grateful for all the support we have received from Swim Across America. For the past thirteen years the support for our efforts has been provided in the form of a Research Fellowship named in honor of Stacey Leondis. The Leondis Family and their circle of family and friends have supported our efforts through these many years, believing the long-stalled progress in improving outcomes of this dreaded disease could be ended. We would never be at the point we are today without their immense dedication and support. We are so optimistic that together we will win this fight. I look forward to once again being able to join Team Stacey and the entire group at the Nassau/Suffolk Long Island Open Water Swim. Thank you all so much for your incredible support.

Hope to see you all soon!

Sincerely,

Richard Gorlick, MD
Division Head and Department Chair, Pediatrics
H. Grant Taylor, M.D., W. W. Sutow, M.D. and Margaret P.
Sullivan, M.D. Distinguished Chair in Pediatrics
Department Chair ad interim, Sarcoma Medical Oncology,
Division of Cancer Medicine
University of Texas MD Anderson Cancer Center
Children's Cancer Hospital



Dr. Richard Gorlick Chair of the department of Pediatrics, MD Anderson Children's Cancer Hospital

His particular area of expertise is developing new therapeutics for the treatment of sarcomas—bone cancer. As a pediatric cancer survivor, Dr. Gorlick has committed his life to finding a cure.

Dr. Gorlick has published more than 80 peer-reviewed articles in leading medical journals and is a frequent invited lecturer in bone tumors at major medical meetings throughout the United States and Europe.

Swim Across America has granted **more than \$2 million** to Dr. Gorlick's osteosarcoma research.

Cold Spring Harbor Labs and The Feinstein Institute @ Northwell Health

 Feinstein Institutes for Medical Research
Northwell Health

December 2023

Dear Swim Across America Friends,

Our laboratory is truly honored and very grateful to be a beneficiary of Swim Across America. The major focus in our laboratory remains to be therapeutically targeting tumor microenvironment (TME) of B cell leukemia and lymphoma. With your support, we have significant findings from the project "Targeting the Tumor Microenvironment to Treat Chronic Lymphocytic Leukemia (CLL)". We found that the molecular CLECL1 not only marks the aggressive clone of CLL, activates T cells to produce IL-4, but also interact with TME, specifically stromal cells within spleens and lymph nodes (LNs). The activated CLL cells enriched of CLECL1+ cells produce lymphotoxin and promote B-cell zone specific stromal cells (follicular dendritic cells, FDCs), but suppress T cell zone fibroblastic reticular cells (FRCs). As the result of these actions, T cell functions are impaired and leukemic B cells retain and gain growth signal in TME. These data highlight how B-cell tumors educate and restructure the stromal cells to promote disease progression. In addition, we have made a huge progress in the generation and production of CLECL1 antagonist antibodies for therapeutic purposes. These studies have accelerated our pattern application, created new collaboration opportunities including those with the industry, and provided us the key preliminary data for grant applications.

We are very excited by the preliminary data and all the proposed experiments. This work is highly translational, the results are highly applicable to almost all the B-cell tumors. Using the established models, we are now initiating our work in Mantle cell lymphoma. We are thankful for your support that accelerates our research, and truly hoping to continue our partnership with SAA to fight cancer.

Sincerely,

Shihshih Chen

Assistant professor
The Feinstein Institute for Medical Research at Northwell Health



Cold Spring Harbor Laboratory is proud to partner with
Team Carolyn and Swim Across America to find
treatments and cures for cancer.

The CSHL Cancer Center is the only National Cancer Institute-designated cancer center on Long Island and is at the forefront of understanding the molecular and cellular basis of human cancer, breaking new ground in tumor biology and developing innovative, advanced technologies.

 Cold Spring Harbor Laboratory





NASSAU-SUFFOLK Long Island

\$10,000 PLATINUM SPONSOR

- Company Tent at Event, Advertising, Logo on Shirts, Social Media and Brochure
- SAA Nassau-Suffolk Sponsorship recognition on SAA website
 - Full-Page Ad in SAA Nassau-Suffolk Yearbook
- Team Naming Rights & Registration for 10 Swimmers

\$5,000 GOLD SPONSOR

- Event Signage, Advertising, Logo on Shirts, Social Media and Brochure
 - SAA Nassau-Suffolk Sponsorship recognition on SAA website
 - Full-Page Ad in SAA Nassau-Suffolk Yearbook
 - Team Naming Rights & Registration for 5 Swimmers

\$2,500 SILVER SPONSOR

- Event Signage, Advertising, Logo on Shirts, Social Media and Brochure
 - SAA Nassau-Suffolk Sponsorship recognition on SAA website
 - Half-Page Ad in SAA Nassau-Suffolk Yearbook
 - Team Naming Rights & Registration for 2 Swimmers



For more information, please contact our
sponsorship chairs.

Dan Kennedy
dankennedy529@gmail.com

Jim Sirignano
jimsirignano@gmail.com